Welcome to our dedicated page for iBio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on iBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into iBio's regulatory disclosures and financial reporting.
iBio, Inc. reported its quarterly results for the period ended September 30, 2025. The company generated $100,000 in revenue, with operating expenses of $6.1 million (R&D $3.6 million; G&A $2.5 million), leading to an operating loss of $5.95 million and a net loss of $5.72 million (loss per share $0.11).
Liquidity strengthened following an August 2025 financing, reflected in $28.1 million of cash and cash equivalents and $21.5 million of available‑for‑sale debt securities, totaling approximately $49.6 million at quarter‑end. Stockholders’ equity increased to $56.0 million. Shares outstanding were 20,254,599 as of September 30, 2025.
The company recognized collaboration revenue and reported contract liabilities of $1.15 million. iBio continues to build a preclinical pipeline focused on obesity and cardiometabolic diseases, with IBIO‑610 (Activin E) highlighted as a lead asset. Management states current liquidity is sufficient to fund operations for at least 12 months from the filing date.
iBio, Inc. filed a Form 8-K and furnished a press release announcing financial results for the quarter ended September 30, 2025. The disclosure appears under Item 2.02 (Results of Operations and Financial Condition) and the press release is included as Exhibit 99.1.
The company states this information is furnished, not filed, and it is not incorporated by reference into other SEC filings. The report is dated November 12, 2025.
iBio, Inc. reported it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after receiving notice from Nasdaq on November 4, 2025. The rule requires a minimum closing bid price of $1.00 per share. The company had previously been notified on July 29, 2025 that it was out of compliance after its stock closed below $1.00 for 30 consecutive business days from June 13, 2025 to July 28, 2025. Nasdaq has indicated the matter is closed, supporting the company’s continued listing on The Nasdaq Capital Market.
iBio, Inc. announced new preclinical pharmacokinetic data for IBIO-610, a potentially first-in-class Activin E antibody. In obese non-human primates, IBIO-610 showed an extended half-life of 33.2 days. Using an allometric scaling model for half-life–extended antibodies, the company reports a predicted human half-life of up to 100 days, which could lower dosing to once every six months and improve patient experience.
The data will be presented by Cory Schwartz, Ph.D., during an oral session at ObesityWeek 2025 in Atlanta, held November 4–7, 2025. The announcement was shared via press release furnished with this report, which includes forward-looking statement disclosures.
iBio (IBIO) reported an insider equity grant: its Chief Financial Officer received 75,000 stock options at an exercise price of $0.893 on 10/20/2025. The options are exercisable starting 10/20/2026 and expire on 10/19/2035.
Vesting is 25% on the one-year anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over 36 months, contingent on continued employment. Following the grant, the officer beneficially owned 75,000 derivative securities, held directly.
iBio, Inc. (IBIO) reported an insider equity grant to its Chief Legal Officer. On 10/20/2025, the officer received a stock option to purchase 55,000 shares of common stock at an exercise price of $0.893 per share.
The option vests with 25% on the one-year anniversary of the grant, then the remainder in equal quarterly installments over 36 months, contingent on continued employment. The option becomes exercisable beginning 10/20/2026 and expires on 10/19/2035. The filing lists ownership of these derivative securities as Direct.
iBio, Inc. (IBIO) reported an insider equity award. Martin Brenner was granted 180,000 stock options at an exercise price of $0.893 on 10/20/2025.
The options vest 25% on 10/20/2026, with the remainder vesting in equal quarterly installments over 36 months, and they expire on 10/19/2035. Following the grant, 180,000 derivative securities are beneficially owned directly. Brenner is the company’s Chief Executive Officer, Chief Scientific Officer, and a Director. The transaction was coded A (grant) on Form 4.
iBio, Inc. is asking shareholders to vote on four proposals at its 2025 Annual Meeting: election of directors; ratification of Grassi & Co., CPAs, P.C. as independent auditors for the fiscal year ending June 30, 2026; an advisory Say-on-Pay vote; and an advisory Say-on-Frequency vote. Proxy materials and the Form 10-K for the year ended June 30, 2025 will be mailed to stockholders and the shareholder list will be available for inspection before the meeting.
The filing discloses executive pay details for Chief Scientific Officer Dr. Martin Brenner: his prior base salary was $405,000, he received interim CEO stipend payments of $7,500 per month, and a grant-date RSU award valued at approximately $91,000. Under a restated employment agreement effective July 1, 2024, his base salary was set at $522,365 with a bonus target of 50% for fiscal year 2025. The proxy explains the company’s peer-group selection (preclinical to Phase I/II biotech, preference for AI-enabled companies, market cap $100M, headcount under 100) and discusses stock-based compensation accounting under ASC Topic 718.
iBio, Inc. reported continued development-stage operations with negative operating cash flow of approximately $15.3 million and an operating capital deficit of about $15.3 million as of June 30, 2025, versus an $18.6 million deficit a year earlier. The company had 19,349,201 shares outstanding at June 30, 2025, up from 8,623,676 a year earlier, reflecting multiple equity financings including a 2025 Private Placement that generated approximately $655,000 and warrant exercises and inducement sales that produced aggregate gross proceeds of about $6.2 million. Material transactions include the acquisition of RubrYc (AI drug-discovery assets and related candidates) and CDMO facility purchases financed in part by a secured term loan and settlement arrangements. The filing describes extensive regulatory, clinical, manufacturing and collaboration risks for its vaccine and antibody programs, significant reliance on third-party manufacturers and collaborators, and previously identified internal control weaknesses that were remediated.
iBio, Inc. filed a Form 8-K to report that it issued a press release announcing its financial results for the fiscal year ended June 30, 2025. The press release is furnished as Exhibit 99.1 to the report.
The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions and will not be incorporated by reference into other SEC filings. The report is signed on behalf of iBio by Chief Legal Counsel Marc A. Banjak.